Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was founded in 1988 and is based in Loveland, Colorado.
Heska Stock Up 0.4 %
Shares of HSKA Stock opened at $93.35 on Wednesday. The company has a quick ratio of 5.50, a current ratio of 6.92 and a debt-to-equity ratio of 0.24. The firm's 50-day moving average is $90.10 and its 200-day moving average is $113.25. Heska has a 52-week low of $79.86 and a 52-week high of $275.94.
Wall Street Analysts Forecast Growth
HSKA has been the topic of several analyst reports. Alliance Global Partners boosted their price target on shares of Heska from $150.00 to $155.00 in a research report on Thursday, May 19th. Piper Sandler boosted their price target on shares of Heska from $165.00 to $170.00 in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to MarketBeat.com, Heska currently has an average rating of "Hold" and an average price target of $184.00.